Office of Medical Marijuana Use reports seed‑to‑sale tracking, lab integration and enforcement activity as patient count tops 900,000

Christopher Kimball, director of the Office of Medical Marijuana Use (OMMU) in the Florida Department of Health, briefed the Senate Health Policy Committee on the state medical‑marijuana program’s operational status, enforcement work and licensing developments.

Kimball said the OMMU now reports more than 900,000 qualified patients in the registry, more than 6,000 caregivers and roughly 2,466 qualified physicians (a figure the director said has fluctuated). He said the office has focused on four areas: implementing seed‑to‑sale integration, maintaining the medical marijuana use registry that controls dispensation, licensing and variance review, and compliance enforcement through inspections and lab sampling.

Kimball said seed‑to‑sale integration is now active for the majority of dispensing operations and labs: 19 of 20 actively dispensing medical‑marijuana treatment centers (MMTCs) are integrated and 8 of 9 private laboratories are integrated with the system used for real‑time traceability. He told senators that in 2024 the department began using real‑time traceability to cross‑check dispensed batches and laboratory certificates of analysis.

On laboratory and product quality, Kimball said the department monitors certificates of analysis and conducts desk audits and on‑site checks; the state public health laboratory in Jacksonville is building capacity to provide a public‑sector testing backstop. He said the department issued 243 notices of violation across MMTCs and certified labs in the cited year and fewer than half of those notices resulted in fines.

Kimball discussed diversion and enforcement. He said thefts reported by licensees and law‑enforcement referrals are the primary way the agency learns about criminal diversion. He said the program has tools — packaged labels, 45 days of camera footage and seed‑to‑sale data — to preserve evidence and coordinate with law enforcement. Kimball said the department may suspend patients upon receipt of credible reports of diversion and that suspensions have occurred in at least one case where the department corroborated the allegation.

Licensing remains a topic of committee interest. Kimball summarized two license tracks discussed at length in the transcript: the litigation‑related (Pickford/Black‑farmer) applicants and the April 2023 competitive batch. He said five Pickford‑related applicants are now licensed and others remain in a cure period; the April 2023 batch produced 22 letters of intent to award in November 2023 and the department is processing petitions and adjudications related to those letters.

Kimball also noted operational details audience members raised: the bulk of dispensed product is in forms measured for smokeable and inhalation routes; packaging and certificates of analysis should identify potency and dosing for patient purchases but questions about labeling and opened packages can complicate downstream identification. On telehealth, he said recertifications for patients have been done by telehealth at a rate exceeding 50 percent since the telehealth recertification pathway was implemented.

Senators asked about market saturation, labeling on packages (especially edibles and pre‑rolled products), and how often diversion to non‑patients is detected; Kimball said the agency does not receive diversion reports every day but treats reports seriously and coordinates evidence preservation with law enforcement. He said agencies and policymakers may wish to consider comparisons with other states if they deliberate caps or other market‑structure changes.